Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New appointments at Cerenis Therapeutics

This article was originally published in Scrip

Executive Summary

Cerenis Therapeutics (France/US), a privately held pharmaceutical company developing novel HDL therapies to treat cardiovascular and other metabolic diseases, has made the following appointments: Tom Brya joins as senior vice-president of business development, having previously served as vice-president and general manager for a biologic CMO start-up at Cardinal Health (now part of Catalent Pharma Services); Christopher Prue, who has 30 years' pharmaceutical industry experience, having held roles at AtheroGenics, Purdue Pharma, Incara Pharmaceuticals, Glaxo Wellcome and The Upjohn Company, becomes vice-president of regulatory affairs; and Dr Cynthia Sundell joins as vice-president of drug development; she formerly led discovery efforts at AtheroGenics.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts